Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer outcomes in patients without radical cystectomy

被引：0
作者：
Kota Iida
Makito Miyake
Kaoru Murakami
Motokiyo Komiyama
Eijiro Okajima
Tomokazu Sazuka
Naotaka Nishiyama
Hiroaki Yasumoto
Takahiro Kimura
Akihiro Ito
Kenichiro Shiga
Atsushi Yamagishi
Hiroshi Kikuchi
Mikio Sugimoto
Rikiya Taoka
Takashi Kobayashi
Takahiro Kojima
Hiroshi Kitamura
Hiroyuki Nishiyama
Kiyohide Fujimoto
机构：
[1] Nara Medical University,Department of Urology
[2] Kyoto University Graduate School of Medicine,Department of Urology
[3] National Cancer Center Hospital,Department of Urology
[4] Nara City Hospital,Department of Urology
[5] Chiba University Graduate School of Medicine,Department of Urology
[6] University of Toyama,Department of Urology, Graduate School of Medicine and Pharmaceutical Sciences for Research
[7] Shimane University,Department of Urology
[8] Jikei University School of Medicine,Department of Urology
[9] Tohoku University School of Medicine,Department of Urology
[10] Harasanshin Hospital,Department of Urology
[11] Yamagata University,Department of Urology, Faculty of Medicine
[12] Hokkaido University Graduate School of Medicine,Department of Urology
[13] Kagawa University,Department of Urology, Faculty of Medicine
[14] University of Tsukuba,Department of Urology, Faculty of Medicine
来源：
International Journal of Clinical Oncology | 2021年 / 26卷
关键词：
Bacillus Calmette-Guérin-unresponsive; Estimated glomerular filtration rate; Non-muscle invasive bladder cancer; Tumor size;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2104 / 2112
页数：8
相关论文
共 72 条
  • [1] Miyake M(2015)Exploration of risk factors predicting outcomes for primary T1 high-grade bladder cancer and validation of the Spanish Urological Club for Oncological Treatment scoring model: long-term follow-up experience at a single institute Int J Urol 22 541-547
  • [2] Gotoh D(2020)Clinical practice guidelines for bladder cancer 2019 update by the Japanese Urological Association: summary of the revision Int J Urol 27 702-709
  • [3] Shimada K(2019)European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)—2019 update Eur Urol 76 639-657
  • [4] Matsumoto H(2017)Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/ASTRO/SUO guideline J Urol 198 552-559
  • [5] Shiraishi K(2012)Prognostic significance of Bacillus Calmette-Guerin failure classification in non-muscle-invasive bladder cancer BJU Int 110 E216-E221
  • [6] Azuma H(2015)Clarification of bladder cancer disease states following treatment of patients with intravesical BCG Bladder Cancer 1 29-30
  • [7] Babjuk M(2016)Bacillus Calmette-Guérin (BCG) treatment failures with non-muscle invasive bladder cancer: a data-driven definition for BCG unresponsive disease Bladder Cancer 2 215-224
  • [8] Burger M(2018)Treatment strategy for newly diagnosed T1 high-grade bladder urothelial carcinoma: new insights and updated recommendations Eur Urol 74 597-608
  • [9] Compérat EM(2020)Bacillus Calmette-Guerin-unresponsive non-muscle-invasive bladder cancer: its definition and future therapeutic strategies Int J Urol 27 108-116
  • [10] Chang SS(2009)A new equation to estimate glomerular filtration rate Ann Intern Med 150 604-612
12345678